This study investigated patient-reported outcomes (PROs) in patients taking upadacitinib (Rinvoq) to treat rheumatoid arthritis (RA). They found that this treatment improved the quality of life (QoL) in these patients.

This study investigated whether thiazolidinediones (TZDs) can help lower the risk of Parkinson’s disease (PD) in patients with type 2 diabetes (T2D). The authors concluded that TZDs were associated with a lower risk of PD in these patients.

This study investigated the effect of dietary fiber supplementation (DFS) in patients with rheumatoid arthritis (RA). They found that DFS may improve RA symptoms.

This study evaluated the safety and effectiveness of switching to insulin degludec (Tresiba) in patients with diabetes mellitus. This study concluded that patients had better blood glucose control and a lower risk of low blood sugar after switching.

This trial is testing the effectiveness of once-daily vs thrice-daily oral insulin in patients with type 1 diabetes (T1D). The main outcome is the amount of injected insulin used, and the second outcome is the amount of time blood glucose levels are within specific ranges. This study is being conducted in Orange County, California, USA.

This study is looking for patients with diabetes taking insulin to test a mobile app that helps patients understand how blood glucose levels change. The main outcome that will be measured is the average blood glucose level at the beginning versus the end of the study. This study is recruiting in Boston, MA, the US.

This study is examining the effectiveness of insulin inhaler Afrezza at mealtimes for patients with type 2 diabetes (T2D). The main outcome of the study will be the time patients’ blood glucose readings are in the ideal range. This study is recruiting in San Antonio, TX, US.

This study examined the frequency of sodium-glucose cotransporter 2 (SGLT2) inhibitor use in type 1 diabetes (T1D) and the resulting rates of diabetic ketoacidosis (DKA). The study concluded that while the proportion of SGLT2 use in T1D is small, there is a significant associated risk of DKA.

This study investigated the safety and effectiveness of different doses of peficitinib (Smyraf; PFC) in treating rheumatoid arthritis (RA). They found that PFC doses of 50 mg or higher were the most effective in these patients.

This study compared the safety and effectiveness of semaglutide (Ozempic) and canagliflozin (Invokana) for patients with uncontrolled type 2 diabetes (T2D). The authors found that semaglutide more effectively reduced blood glucose levels and body weight than canagliflozin.